/Lists

Biotech Late Stage Investors & VC Firms

360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.

NovaCapital
Seed–Late Stage
9 people
Sodero
NantesSeed–Late Stage$162K – $5.4M
19 people
CTI Life Sciences Fund L.P.
MontréalSeed–Late Stage
9 people
AbbVie
CambridgeSeed–Late Stage$300K – $3M
13 people
Gilead Sciences
Foster CitySeries B–Late Stage
19 people
Perscitus LLP
LondonPre-Seed–Late Stage
10 people
Quadrille Capital
ParisSeed–Late Stage
15 people
Scottish Mortgage Investment Trust PLC
EdinburghSeed–Late Stage
18 people
CITIC Capital Holdings
Hong KongGrowth–Late Stage
20 people
Owl Rock Capital
New YorkGrowth–Late Stage
14 people
Bridge Bank
San FranciscoSeed–Late Stage
16 people
Excel Venture Management
BostonSeries A–Late Stage$1M – $5M
7 people
Intermediate Capital Group
LondonGrowth–Late Stage$5M – $50M
16 people
Bonitás Ventures
BudapestGrowth–Late Stage$540K – $4.3M
18 people
IRDI SORIDEC Gestion
ToulouseSeed–Late Stage$216K – $16.2M
17 people
PAI Partners
ParisGrowth–Late Stage$108M – $324M
13 people
IDG Capital Vietnam
HanoiSeed–Late Stage$250K – $3M
13 people
Sambrinvest
CharleroiSeries A–Late Stage
13 people
AbCellera
VancouverSeries B–Late Stage
26 people
Innovatus Capital Partners
New YorkSeed–Late Stage
19 people
Commodore Capital
New YorkSeries C–Late Stage
16 people
iNetworks
PittsburghSeed–Late Stage
11 people
6 Dimensions Capital
Grand CaymanSeed–Late Stage
17 people
Cultivian Sandbox Ventures
ChicagoSeed–Late Stage$5M – $15M
8 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.